This clinical-stage biotech focused on cystic fibrosis therapies reported a notable insider sale amid a year of sharp ownership reductions.
A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million
This clinical-stage biotech focused on cystic fibrosis therapies reported a notable insider sale amid a year of sharp ownership reductions.